Short Interest in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Declines By 72.3%

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the recipient of a large drop in short interest in March. As of March 31st, there was short interest totalling 62,600 shares, a drop of 72.3% from the March 15th total of 225,900 shares. Based on an average daily volume of 1,480,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 3.9% of the shares of the stock are short sold.

Sonoma Pharmaceuticals Stock Down 9.2 %

NASDAQ:SNOA opened at $2.36 on Thursday. Sonoma Pharmaceuticals has a 52-week low of $1.75 and a 52-week high of $9.37. The firm has a market cap of $3.81 million, a P/E ratio of -0.59 and a beta of 1.68. The business’s 50-day moving average price is $2.57 and its 200 day moving average price is $2.70.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last released its quarterly earnings data on Wednesday, February 5th. The company reported ($0.59) earnings per share for the quarter. Sonoma Pharmaceuticals had a negative return on equity of 68.98% and a negative net margin of 26.82%. Sell-side analysts expect that Sonoma Pharmaceuticals will post -0.67 EPS for the current year.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.